Categories : Endocrine & Metabolic
Product Packaging : 10 / 30 tablets
Product Composition : 20 mg + 30 mg
Send MessageTeneligliptin & Pioglitazone Tablets are a fixed-dose oral antidiabetic combination designed to address multiple pathophysiological defects in type 2 diabetes mellitus. This formulation combines Teneligliptin, a potent DPP-4 inhibitor that enhances incretin activity, with Pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ receptors in peripheral tissues.
The combination delivers complementary benefits—Teneligliptin improves glucose-dependent insulin secretion and suppresses glucagon release, while Pioglitazone enhances cellular responsiveness to insulin in muscle and adipose tissues. Together, they provide a balanced approach to glycemic control, targeting both pancreatic function and insulin resistance.
Genliva Wellness LLP, Himatnagar, India, is a dependable teneligliptin pioglitazone tablet manufacturer India, offering high-quality combination antidiabetic formulations for domestic supply, export markets, and contract manufacturing collaborations.
Teneligliptin & Pioglitazone Tablets are advanced combination antidiabetic medicines designed to target insulin resistance and impaired glucose regulation in type 2 diabetes mellitus. The combination improves insulin sensitivity while enhancing incretin-mediated glucose control for better metabolic performance.
These tablets are prescribed for patients with type 2 diabetes who require improved insulin sensitivity and stable long-term glucose regulation. They are particularly beneficial in patients with metabolic imbalance and poor glycemic control on monotherapy.
Teneligliptin & Pioglitazone Tablets provide multi-pathway glucose management with enhanced insulin action and durable glycemic control, supporting improved diabetic outcomes.
